Medtech & Pharma Platform Association

What Medtech & Pharma Platform Association does

The Medtech & Pharma Platform Association (MPP) is a Basel, Switzerland-based non-profit industry association founded in 2017. It convenes pharmaceutical, medical device, diagnostics, and technology companies around the regulatory, development, and commercialization challenges of combined health technologies and combination products. Its membership spans 20+ companies including Roche, Novartis, MSD, Bayer, Boehringer Ingelheim, Ypsomed, BD, Labcorp, Gerresheimer, BioMarin, and MDx CRO. MPP operates through working groups (including a Connected Combined Products group), an annual conference series that has run 11 editions with 190+ attendees, and direct advocacy with European regulators such as the EMA and the European Commission.

The association's core outputs are policy positioning and stakeholder convening rather than commercial products. It maintains recognized stakeholder status with the EMA and is registered in the EU Transparency Register, providing a structured channel for members to influence the development of EU medical device (MDR), in-vitro diagnostic (IVDR), and AI regulations. Recent outputs include an October 2024 position paper on IVDR's impact on in-house devices used in clinical trials, a March 2024 statement on the AI Act, and a December 2025 response to the European Commission's proposed amendments to MDR and IVDR.

MPP runs on a membership and event revenue model: members pay dues, and the annual conference is monetized through sponsorship (around CHF 5,000) and exhibitor (around CHF 2,500–3,000) packages. The organization is small (1–10 employees) and does not publicly disclose its financials. Its strategic value to members is access to a coordinated regulatory voice and a cross-industry forum on combination products that individual firms would struggle to replicate alone.

Name

Medtech & Pharma Platform Association

Legal name

Medtech & Pharma Platform Association

Website

https://medtech-pharma.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Medtech & Pharma Platform Association (MPP) is a Basel-based non-profit industry association, founded 2017, that convenes 20+ pharma, medtech, diagnostics, and tech companies on combined health technologies via working groups, an annual conference, and EU regulatory advocacy.

Ownership category

akta.pro rank

Product category

Industry Association Services

NAICS

Business Associations (813910)

SIC

Services-Membership Organizations (8600)

akta.pro primary industry

Technical Committees, Working Groups & Expert Panels (BPADANAB)

Keywords

• Regulatory advocacy services
• Industry association membership
• Combined health technologies
• Policy working groups
• Annual conference events

Headquarters

HQ city

Basel, Basel-Stadt

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Membership Fees: The MPP generates revenue through membership fees from pharmaceutical, medtech, diagnostic, and tech companies. Members gain access to working groups, news alerts, policy intelligence, scientific network, and reduced conference fees.
2. Conference Revenue: Revenue from annual conference sponsorships and exhibitor packages. Sponsor package (CHF 5000) includes 3 complimentary tickets, tabletop exhibit, logo placement, and social media. Exhibitor package (CHF 2500-3000) includes conference tickets and logo visibility.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

The MPP Association is a European not-for-profit industry association that brings together pharmaceutical, medtech, diagnostic, and digital technology companies active in combined health products. It delivers paid membership services including participation in regulatory working groups, access to news and policy intelligence, stakeholder dialogue with regulators, an annual conference, and published position papers on EU regulatory frameworks such as MDR, IVDR, pharmaceutical legislation, and the AI Act.

Product overview

The Medtech & Pharma Platform (MPP) Association is a European industry association—not a product company—focused on combined health technologies that merge medicinal products, medical devices, and digital technologies. The MPP provides a platform for advocacy, knowledge exchange, and networking through its Annual Conference, Working Groups (Combined Products, Connected Combined Products, IVD), Publications, Events/Webinars, and Networking services. The association bridges the pharma, medtech, diagnostic, and tech sectors to achieve a balanced regulatory framework for combined products in Europe.

Differentiator

Problem solved

Functional benefit

Products and services

• Annual Conference (MPP Annual Conference) Annual flagship conference held each year in Basel bringing together industry, regulatory authorities, Notified Bodies, patient organizations, and academia to discuss combined health products. Features expert presentations, panel discussions, and networking opportunities. Sponsorship packages and exhibitor packages are sold as standalone offerings.
• MPP Association Membership Recurring membership offering for pharmaceutical, medtech, diagnostic, and tech companies. Members gain participation rights in working groups, news and policy intelligence on combined products, access to the scientific network, reduced conference fees, and direct stakeholder interactions with regulators and notified bodies.
• Conference Sponsorship and Exhibitor Packages Paid sponsorship and exhibitor packages for the Annual Conference. Sponsor Package (CHF 5,000) includes 3 complimentary tickets, a tabletop exhibit, logo placement on website/onsite/communications, and a social media announcement. Exhibitor Package (CHF 2,500–3,000+) includes conference tickets and logo visibility.

Quantifiable outcome

• Over 190 participants from industry, health and regulatory authorities, notified bodies, patient organizations and academia attended MPP 2024 Annual Conference
• +2 more outcomes

Named customers16 records

Segments7 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

20 partnerships are on record, tiered core and minor.

• NovartiscoreStrategic or Co-development Partner · 3 September 2024Novartis hosted the 11th MPP Annual Conference on September 3, 2024 at the Novartis Campus in Basel. Mike Wallenstein served as Chair of the 2024 Annual Conference Program Committee.
• US FDA (Office of Combination Products)coreStrategic or Co-development Partner · 3 September 2024James Bertram, Director of the Office of Combination Products at the US FDA, participated as panelist at MPP 2024 Conference providing international regulatory perspectives.
• European Medicines Agency (EMA)coreStrategic or Co-development Partner · 3 September 2024Virginia Rojo, Head of the Procedures Office at EMA, participated as panelist at MPP 2024 Conference. MPP is a recognized EMA stakeholder.
• SwissmediccoreStrategic or Co-development Partner · 3 September 2024Karolyne Mathys, Head of Medical Devices Surveillance at Swissmedic, participated as panelist at MPP 2024 Conference. Swissmedic has representatives on the Program Committee.
• Notified Bodies (Team-NB, BSI)coreStrategic or Co-development Partner · 3 September 2024Representatives from Team Notified Body (Team-NB) and BSI participated in MPP 2024 Conference panels. Notified bodies are key stakeholders in combined product regulation.
• Patient OrganizationscoreStrategic or Co-development Partner · 3 September 2024Patient advocacy groups participated in MPP 2024 Conference sessions on patients' inclusion and perspectives on lifecycle of combined products.
• MDx CROcoreStrategic or Co-development Partner · 3 July 2024MDx CRO joined the MPP Association. MDx CRO contributes expertise in clinical research and diagnostics to the combined products ecosystem.
• GerresheimercoreStrategic or Co-development Partner · 16 May 2024Gerresheimer joined the MPP Association in May 2024. Gerresheimer provides drug delivery systems and contributes to efforts for balanced regulatory framework for combined products.
• NovartiscoreStrategic or Co-development Partner · 29 April 2024Novartis is a member company of the MPP Association. Manfred Mäder from Novartis was elected as Designated Vice-President of the Board of Directors at the 2024 General Assembly. Novartis contributes to MPP's mission of achieving a balanced regulatory framework for combined products in Europe.
• YpsomedcoreStrategic or Co-development Partner · 29 April 2024Ypsomed is a member company represented by Stephan Affolter on the MPP Board of Directors. Ypsomed contributes expertise in drug delivery systems and hosts conference program committee leadership.
• RochecoreStrategic or Co-development Partner · 29 April 2024Roche is a member company represented by Stephanie Horn on the MPP Board of Directors. Roche contributes expertise in pharmaceuticals and diagnostics to combined product regulatory discussions.
• Swiss MedtechcoreStrategic or Co-development Partner · 29 April 2024Swiss Medtech is a member company represented by Daniel Delfosse on the MPP Board of Directors. The association is headquartered in Switzerland.
• BD (Becton Dickinson)coreStrategic or Co-development Partner · 29 April 2024BD is a member company represented by Fanny Barbotin on the MPP Board of Directors. BD contributes expertise in medical devices and diagnostics.
• MSDcoreStrategic or Co-development Partner · 29 April 2024MSD (Merck & Co.) is a member company represented by Ruth Foster on the MPP Board of Directors. MSD contributes pharmaceutical and combined product expertise.
• Shayesteh Fürst-LadanicoreStrategic or Co-development Partner · 29 April 2024Re-elected as President of the MPP Board of Directors. Provides leadership and strategic direction to the association.
• LabcorpcoreStrategic or Co-development Partner · 15 January 2024Labcorp joined the MPP Association in January 2024. As a leading life sciences company, Labcorp's membership reinforces MPP's capabilities in diagnostics and laboratory services.
• Novo NordiskcoreStrategic or Co-development Partner · 1 January 2024Thomas Wejs Møller from Novo Nordisk serves as Chair of the 2026 Program Committee. Novo Nordisk contributes to conference programming and regulatory discussions.
• TÜV SÜDcoreStrategic or Co-development Partner · 1 January 2024Sabina Hoekstra-van den Bosch from TÜV SÜD serves on the Program Committee, representing notified body perspective in combined product discussions.
• CompcureminorStrategic or Co-development Partner · 1 January 2024Marianne Silkjær Nielsen from Compcure serves on the Program Committee, contributing expertise in regulatory and clinical matters.
• BioMarin PharmaceuticalcoreStrategic or Co-development Partner · 1 January 2023BioMarin Pharmaceutical joined the MPP Association to build bridges between medtech, pharma and digital fields and contribute to achieving balanced regulatory framework for combined products.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Combination Products Coalition: The Combination Products Coalition is a US industry coalition focused on regulatory and scientific issues affecting drug-device and biologic-device combination products. Its sector-specific advocacy and information-sharing model closely parallels MPP's work for companies developing combined health technologies.

Emerging players

• EuropaBio: EuropaBio is a European biotechnology industry association focused on innovation, regulation and policy advocacy for its members. It is relevant because its corporate constituency, public-affairs work and European policy engagement partially overlap with MPP, despite biotech being a broader category.
• Drug Information Association: DIA is a global, neutral membership association for life-sciences professionals that convenes conferences, training and knowledge exchange across drug development and regulation. Its nonprofit association model and event-led engagement are comparable to MPP, though DIA spans a much broader life-sciences agenda.
• Regulatory Affairs Professionals Society: RAPS is a global professional membership organization serving healthcare-product regulatory professionals through education, events, publications and networking. It is comparable to MPP's regulatory knowledge-exchange and community model, but its members are primarily individuals rather than corporate organizations.
• The Organisation for Professionals in Regulatory Affairs: TOPRA is a professional membership body for regulatory affairs in human and veterinary medicines, providing events, training, publications and a specialist network. It overlaps with MPP's regulatory intelligence and stakeholder-engagement activities but serves a narrower medicines-focused professional community.

Broad incumbents

• MedTech Europe: MedTech Europe is the principal European trade association for the medical technology industry and engages in EU regulatory policy, market access and industry representation. It is comparable to MPP because many of its member companies overlap with MPP, although its remit is broader and medtech-focused.
• Advanced Medical Technology Association: AdvaMed is a large US medical-technology industry association that advocates on regulation, reimbursement, standards and market access. It is relevant to MPP because both represent medtech stakeholders and engage on combination-product policy, but AdvaMed has a broader national remit.
• European Confederation of Pharmaceutical Entrepreneurs: EUCOPE is a European industry association representing small and mid-sized pharmaceutical and biotechnology companies. It is comparable to MPP through corporate memberships, policy advocacy and regulatory engagement, although it is not specialized in drug-device combination products.
• European Federation of Pharmaceutical Industries and Associations: EFPIA represents the research-based pharmaceutical industry in Europe and participates in healthcare, regulatory and innovation policy. It is comparable to MPP through its corporate membership and public-affairs model, but it covers conventional pharmaceuticals more broadly than combination products.

Regional players

• Swiss Medtech: Swiss Medtech is a national industry association representing Switzerland's medical-technology sector and is itself connected to MPP through membership and board representation. It is geographically and operationally comparable in regulatory advocacy and member services, but its remit is Swiss and medtech-specific.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/medtech__pharma?lang=de
• LinkedInlinkedin.com/company/medtech-&-pharma-platform

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medtech & Pharma Platform Association